Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 3/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.31 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25216174 | 0.96 | RET (0.32) | RETKDM4DBTKGPR119CYP46A1 | |
| SCHEMBL25268724 | 0.96 | RET (0.32) | RETKDM4DBTKGPR119CYP46A1 | |
| SCHEMBL29418521 | 0.89 | BTK (0.44) | RETKDM4DBTKAAK1PIK3CD | |
| SCHEMBL29418528 | 0.87 | BTK (0.44) | RETKDM4DBTKAAK1PIK3CD | |
| SCHEMBL29418352 | 0.84 | BTK (0.45) | RETKDM4DBTKAAK1PDE10A | |
| SCHEMBL29418362 | 0.83 | KDM4D (0.40) | RETKDM4DBTKAAK1GPR119 | |
| SCHEMBL29418505 | 0.81 | PIK3CD (0.39) | RETKDM4DBTKPIK3CDKIF18A | |
| SCHEMBL25248305 | 0.80 | BTK (0.46) | BTKATR | |
| SCHEMBL25248307 | 0.80 | BTK (0.46) | BTKATR | |
| SCHEMBL29418431 | 0.80 | PIK3CD (0.39) | RETKDM4DBTKAAK1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | RET 225/4885KDM4D 1396/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.